New combo pill aims to tackle fatty liver, obesity, and diabetes at once
NCT ID NCT07570810
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether adding an experimental drug (CS0159) to a standard diabetes medication (semaglutide) can help people with fatty liver disease, obesity, and type 2 diabetes lose weight and improve their health. About 30 adults will take the combination or a placebo for 12 weeks. The main goals are to see how much weight they lose and how their body uses energy, while also checking for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?